Zobrazeno 1 - 10
of 193
pro vyhledávání: '"Phase 0"'
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract The COVID-19 pandemic has highlighted the importance of efficient drug discovery in respiratory disease. The traditional set up of clinical trials is expensive and allows for significant attrition of new drugs, many of which undergo extensiv
Externí odkaz:
https://doaj.org/article/8ac80f945eeb4d6880f8470487d1661b
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Intra-Target Microdosing (ITM), integral to Phase 0 clinical studies, offers a novel approach in drug development, effectively bridging the gap between preclinical and clinical phases. This methodology is especially relevant in streamlining early dru
Externí odkaz:
https://doaj.org/article/964904260afd4e1d9f72395df60255d0
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/46456125c85447cf99ea61865712ac09
Autor:
Kenneth R. Gundle, Karthik Rajasekaran, Jeffrey Houlton, Gary B. Deutsch, Thomas J. Ow, Robert G. Maki, John Pang, Cherie-Ann O. Nathan, Daniel Clayburgh, Jason G. Newman, Elyse Brinkmann, Michael J. Wagner, Seth M. Pollack, Matthew J. Thompson, Ryan J. Li, Vikas Mehta, Bradley A. Schiff, Barry I. Wenig, Paul L. Swiecicki, Alice L. Tang, Jessica L. Davis, Annemieke van Zante, Jessica A. Bertout, Wendy Jenkins, Atticus Turner, Marc Grenley, Connor Burns, Jason P. Frazier, Angela Merrell, Kimberly H. W. Sottero, Jonathan M. J. Derry, Kate C. Gillespie, Bre Mills, Richard A. Klinghoffer
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Drug development is systemically inefficient. Research and development costs for novel therapeutics average hundreds of millions to billions of dollars, with the overall likelihood of approval estimated to be as low as 6.7% for oncology
Externí odkaz:
https://doaj.org/article/df356ddd88154387999a5c867f337370
Autor:
A. F. Roffel, E.-J. van Hoogdalem
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Phase 0 microdosing studies were introduced to the drug development community approximately 20 years ago. A microdose is defined as less than 1/100th of the dose calculated based on animal data to yield a pharmacological effect in humans, with a maxi
Externí odkaz:
https://doaj.org/article/6c355cef4c7f46e4b9e58f9329243ad2
Autor:
Miguel Quintela-Fandino, Juan V. Apala, Diego Malon, Silvana Mouron, Javier Hornedo, Lucia Gonzalez-Cortijo, Ramon Colomer, Juan Guerra
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-14 (2019)
Abstract Background The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulat
Externí odkaz:
https://doaj.org/article/1917c626fbb948caba36756bcb86cc27
Autor:
Shyh-Jen Wang, Wen-Sheng Huang, Chi-Mu Chuang, Chih-Hsien Chang, Te-Wei Lee, Gann Ting, Ming-Huang Chen, Peter Mu-Hsin Chang, Ta-Chung Chao, Hao-Wei Teng, Yee Chao, Yuh-Min Chen, Tzu-Ping Lin, Ya-Jen Chang, Su-Jung Chen, Yuan-Ruei Huang, Keng-Li Lan
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-13 (2019)
Abstract Background Liposomes are drug nano-carriers that are capable of targeting therapeutics to tumor sites because of enhanced permeability retention (EPR). In several preclinical studies with various tumor-bearing mice models, 188Re-liposome tha
Externí odkaz:
https://doaj.org/article/1e9dd843d53f498f91b032a8bb5e482a
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The evaluation of antibody-targeted or peptide-targeted radiopharmaceuticals as monotherapy or in oncological drug combinations requires programmatic collaboration within the National Cancer Institute (NCI) clinical trial enterprise. Phase 0 trials p
Externí odkaz:
https://doaj.org/article/2e9f95793f5b495da3b70293cc8a85cc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.